CEO of Australian Prostate Cancer Research Clinches Global Oncology Prize

Pinterest LinkedIn Tumblr +

Mark Harrison C3 Prize PitchCEO of Australian Prostate Cancer Research (APCR), Mark Harrison, Melbourne, has clinched a global AUD $32,840 oncology grant for his role in developing APCR’s interactive online prostate treatment support service, PROSTMATE™.

Mr Harrison was awarded one of two first prizes in the Astellas Oncology C3 Prize – a global challenge designed to inspire non-medicine innovations to improve the cancer care experience for patients, carers and their loved ones – during a red carpet announcement at the European Society of Medical Oncology (ESMO) Annual Congress in Copenhagen, Denmark this week.

Attracting more than 100 entries from patients, carers, health care providers and technology entrepreneurs worldwide, PROSTMATE™ was named one of three inaugural winning entries after five finalists pitched their ideas live at Stanford University’s Medicine X to a panel of judges. This win demonstrates Australia’s leadership in developing world-class solutions for cancer care.

According to Mr Harrison, PROSTMATE™ provides digital tools to help prostate cancer patients track their cancer journey, treatments and appointments, and offers a selection of self-help modules to enhance health and wellbeing. PROSTMATE™ also provides users access to online tele-health consults where patients, family members and friends can connect with prostate cancer experts in the comfort of their own home.

“Many Australian men with prostate cancer face difficulties accessing appropriate, qualified and timely clinical intervention and support, particularly those living in rural, regional and remote areas. We are trying to solve the unmet need in this community through a companion-based program designed to provide a tailored experience,” said Mr Harrison.


About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Comments are closed.